ABL Bio-Technologies Ltd vs TORRENT PHARMACEUTICALS L

A side-by-side comparison of ABL Bio-Technologies Ltd (526955) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, TORRENT PHARMACEUTICALS L leads 526955 vs TORNTPHARM on 9 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability04
  • Growth· not comparable
  • Size & financial health13

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

0.00
P/E ratio
77.60
0.00
P/B ratio
18.67
0.00%
Dividend yield
0.76%
₹-0.22
EPS
₹63.92

Profitability

TORNTPHARM takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

-0.97%
Return on equity
27.40%
-0.50%
Return on capital
15.00%
0.00%
EBITDA margin
33.00%
0.00%
Net margin
15.29%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

Revenue CAGR (3Y) even
13.27%
Profit CAGR (3Y) even
19.75%

Size & financial health

TORNTPHARM takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹0 Cr
Market cap
₹1.88L Cr
₹0 Cr
Revenue
₹13,980 Cr
₹-0 Cr
Net profit
₹2,138 Cr
0.00
Debt / equity
1.69
ABL Bio-Technologies Ltd
  • + ["Stock is trading at 0.04 times its book value"]
  • ["Company has low interest coverage ratio.", "Company has a low return on equity of -31.8% over last 3 years.", "Contingent liabilities of Rs.4.52 Cr.", "Company might be capitalizing the interest cost"]
TORRENT PHARMACEUTICALS L
  • + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
  • ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
ABL Bio-Technologies Ltd full analysis TORRENT PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.